Navigation Links
Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
Date:7/20/2009

AIEA, Hawaii, July 20 /PRNewswire/ -- The Centers for Disease Control and Prevention reported this week that the prevalence of obesity among Americans is now over 26%. Obesity exacerbates a constellation of diseases including diabetes, liver disease, and heart disease, often in the same patient, and is referred to as "metabolic syndrome." Low level inflammation and oxidative stress are the mechanistic underpinnings of metabolic syndrome.

The Cardax lead compound is a novel and highly bioavailable proprietary derivative of the natural dietary carotenoid astaxanthin that addresses metabolic syndrome, including liver and cardiovascular disease as well as diabetes. Preclinical animal studies with the Company's compounds or its active metabolite have demonstrated reductions in blood pressure, triglycerides, cholesterol levels, C-reactive protein, and fasting blood glucose levels. Enzyme levels indicative of liver damage, such as ALT and AST, are decreased, pointing to an outstanding safety profile. Increases in HDL, the "good" cholesterol and increased insulin sensitivity have also been documented along with a robust improvement in thrombosis and myocardial salvage.

The Cardax drug reduces systemic inflammation and oxidative stress while localizing in the liver and the vasculature. Cellular studies have determined that this compound acts as a plasma and mitochondrial membrane stabilizer and a potent antioxidant.

"Cardax has pioneered a novel approach to treating the source of inflammation, intracellular oxidative stress," said David G. Watumull, CEO of Cardax. "We believe this to be a new paradigm for the treatment of liver and cardiovascular disease as well as metabolic syndrome."

"Our novel derivative of the natural carotenoid astaxanthin exhibits dramatically improved bioavailability relative to the parent compound," adds Chief Medical
'/>"/>

SOURCE Cardax Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
2. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
5. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
6. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
7. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
8. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
9. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
10. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
11. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014   Royal Philips ... announced it has received 510(k) clearance from the ... precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) ... provides interventionalists with pre-procedural, high-precision positioning to treat ... planning application is available as part of Philips ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Indiana blocked the sale of more ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Calif., Oct. 28 Watson Pharmaceuticals, Inc. (NYSE: ... announced today that its subsidiary Watson Laboratories, Inc. ... on outstanding patent litigation related to Watson,s Oxytrol® ... August 19, 2008, Barr submitted an Abbreviated New ...
... 27 Cambrex Corporation (NYSE: CBM ) announced that third quarter 2009 financial results will be ... conference call to discuss the third quarter 2009 financial results. , , ... 2009 Earnings Conference Call, When: ... 1-888-634-4003 for U.S., ...
Cached Medicine Technology:Watson and Barr Settle Lawsuit Over Oxytrol(R) 2
(Date:8/21/2014)... DURHAM, NC -- Researchers have pinpointed the environmental source ... in Southern California for decades. It literally grows on ... project of a 13-year-old girl, who spent the summer ... Angeles hardest hit by infections of the fungus named ... Cryptococcus , which encompasses a number of species ...
(Date:8/21/2014)... California (PRWEB) August 21, 2014 The ... initial plans for entertainment and programming for its inaugural ... On Sunday, October 12, 2014, from 11 a.m. to ... closed to all cars and the downtown will be ... activities, curated by Community Arts Resources (CARS), for all ...
(Date:8/21/2014)... (HealthDay News) -- Not only is eating better and exercising ... of health-care dollars a year, a new study finds. ... health sciences at Wake Forest Baptist Medical Center in Winston-Salem, ... 2 diabetes patients. Participants ranged in age ... an intensive "lifestyle change program" focused on diet and exercise, ...
(Date:8/21/2014)... seniors, dimming vision may be tied to poorer survival, new ... aged 65 to 84, who were assessed when they enrolled ... later. Vision loss over time was associated with an ... period, the researchers reported. Although the study couldn,t prove ... University in West Lafayette, Ind., offered up some theories on ...
(Date:8/21/2014)... The W. Montague Cobb/ NMA Health ... voice in the elimination of health disparities, honored ... 112th National Medical Association’s (NMA) Annual Convention and ... Ruffin, Ph.D, former Director of the National Institute ... career and innovations have had a significant impact ...
Breaking Medicine News(10 mins):Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2
... is associated with a statistically significant increase in cancer risk ... of the breast, liver, rectum, and upper aero-digestive tract combined, ... of the Journal of the National Cancer Institute. ... known about the impact of low to moderate alcohol consumption ...
... are sent to a cardiologist to go through a standard ... evidence of coronary artery disease which is the most common ... in men, and these women are sent home with little ... complaining of similar symptoms and are more likely to develop ...
... Postpartum depression is a seriousand often undiagnosedcondition affecting about ... the causes might include personal history of depression, stressful ... support. Left untreated, it can have lasting negative effects ... development. , In the first study of ...
... And that can pose a big public health threat, ... Following their release from Texas prisons, only 5 percent ... to treat their condition within the necessary 10 days, ... [antiretroviral therapy] at this time are at increased risk ...
... Experts agree that field needs more rigorous trials to aid ... of the guidelines for cardiac care issued by the American ... supported by the kind of gold-standard evidence that doctors respect ... come from heretics crying in the wilderness. One author of ...
... Telekenex, Inc ("Telekenex"), today announced it has ... MPLS network over the weekend from Straitshot Communications ... the challenge and worked straight through the weekend ... its network. One of these companies, Evergreen ...
Cached Medicine News:Health News:Million women study shows even moderate alcohol consumption associated with increased cancer risk 2Health News:Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain 2Health News:Diabetes a risk factor for postpartum depression 2Health News:Most HIV-Infected Prisoners Go Untreated After Release 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 2Health News:Weak Evidence Backs Most Heart Guidelines, Report Finds 3Health News:Evergreen Healthcare and Others Successfully Migrate to the Telekenex Network From Straitshot 2
Single-Piece PMMA Intraocular Lenses....
Single Piece PMMA Lens (Refractive and Bifocal). Anterior chamber Lens....
Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
STABIBAG Hydrophilic Acrylic Lens....
Medicine Products: